Antidepressants for insomnia in adults

Area of Science:

• Pharmacology
• Sleep Medicine
• Psychiatry

Background:

• Insomnia disorder significantly impairs quality of life and increases risks for mental and physical health issues.
• Hypnotic medications are common but carry risks of tolerance and dependence.
• Antidepressants are widely used for insomnia despite lacking specific licensing and having unclear efficacy.

Purpose of the Study:

• To evaluate the effectiveness, safety, and tolerability of antidepressant medications for treating insomnia in adults.

Main Methods:

• Systematic review of randomized controlled trials (RCTs) identified through comprehensive database searches up to July 2015 (updated to December 2017).
• Included RCTs involved adults (≥18 years) with primary insomnia, including those with comorbidities.
• Analyzed antidepressants (monotherapy) compared against placebo, other insomnia medications, or usual care.

Main Results:

• Tricyclic antidepressants (TCAs) showed moderate improvement in subjective sleep quality and possibly sleep efficiency and duration compared to placebo.
• Selective serotonin reuptake inhibitors (SSRIs) had uncertain effects, with limited evidence from small studies.
• Trazodone demonstrated moderate improvement in subjective sleep outcomes, but with potential for increased adverse effects.

Conclusions:

• Limited, small, and short-term studies restrict definitive conclusions on antidepressant efficacy for insomnia.
• Low-dose doxepin and trazodone may offer short-term sleep quality improvements, but tolerability and safety remain uncertain.
• High-quality trials are essential to establish the role of antidepressants in insomnia management, especially given the lack of evidence for amitriptyline.